Omicron, surely that’s enough

What have the scientific, pharmaceutical, and medical communities done to stifle SARS-CoV-2 infections? There are currently 18 advanced trials of different vaccines, 64 possible new treatments, and 23 potential or approved anti-viral drugs.

The mRNA vaccines from Pfizer and Moderna provide robust protection. (The mRNA technology is being expanded to HIV, malaria, and other diseases for which conventional vaccines have failed.) mRNA vaccines are expensive and need to be shipped frozen. Lower income countries require an effective vaccine that is inexpensive, survives at higher temperature and can be made locally.  Corbevax, created at Baylor College of Medicine, fits these criteria and is currently being made in hundreds of millions of doses in India. Other vaccines (Novovax) produce antibodies to viral proteins in addition to the Spike protein. The Novovax vaccine contains no genetic material.

Beyond vaccines there are 64 new treatments in development that block or slow infection or some of its consequences, like inflammation. Inflammation makes blood vessels leaky; defensive cells, which rush to the site of infection, squeeze out of the circulation, and infiltrate the lungs. They fill air sacs with dead neutrophils, eosinophils, and fluid, making the patient struggle to breathe.  In addition to the inflammatory reaction, when these cells die they release digestive enzymes that can do terrible damage to the lungs or other infected tissues. The use of steroids to inhibit inflammation was a critical early discovery. According to a review I read recently, it is still the best early intervention. Most viruses have means to inhibit a host’s immune system:  some inhibit interferon synthesis, a critical mobilizer of the immune response; SARS-CoV-2 inhibits the production of Natural Killer cells, which recognize infected lung cells and kill them. The more we know about these mechanisms the better off we will be.

There are currently 23 antivirals approved or in testing, including Merck’s Molnupiravir and Pfizer’s Paxlovid, but others have Emergency Use Authorizations as well. Paxlovid, if taken within 5 days of the onset of symptoms, blocks disease progression and keeps 90% of patients from hospitalization.  As a result, our hospitals are able to function, saving money, reducing misery and increasing morale.  Vaccinated and boosted people usually have a short illness unless they have other complications and may not need these therapeutics. But for those who do, or are unvaccinated the drugs are becoming available in pharmacies.

My friend, Jonathan Sanoff, keeps track of these things. He told me about a site called the Therapeutics Locator, which The Assistant Secretary for Preparedness and Response at The Department of Health and Human Services and her staff have prepared. The Assistant Secretary is Rear Admiral Rachel L. Levine, MD. The site tells potential patients where to find these drugs, whether they are in Puerto Rico or Alaska. For skeptics, the site also includes the number of doses on hand at each site and the total made so far, as well as information on each drug. As new therapies come online, they will appear on the Therapeutics Locator. There are currently seven drugs and monoclonal antibodies on the site. The Asst Secretary and her staff do not get much credit, but they should. See: www.covid-19-therapeutics-locator-dhhs.hub.arcgis.com/.

It is important to have many anti-viral drugs, and I was surprised to learn that 23 are still in late clinicals trials. We learned from HIV therapy that an RNA virus can develop resistance to a single drug but cannot evolve resistance to three drugs and is why the number 23 is a pleasant surprise. An even better surprise is, some of these drugs inhibit other RNA viruses, including Zika and Ebola.

Nothing in science or medicine must work, no matter how clever the idea. We should not be surprised that 26 vaccines failed, 92 treatments did not pass muster, and 54 antivirals did not inhibit SARS-CoV-2.  These results on therapies in the development pipeline have been collected by Heidi Ledford, one of Nature Magazine’s senior reporters (Nature, March 3, 2022). I am grateful to her. In that context, the March 11 issue of Science, the flagship publication of the American Academy of Sciences, contains a detailed comparison and analysis of these treatments and ideas on what we need to prepare for the next epidemic. Pandemics are too large a subject to cover everything — we have left out the value of logistics and convincing people to take vaccines, not to mention long Covid, but people are studying these challenges. The combination of basic science, private industry, and public health services have done well, although praise sounds hollow when millions have died.

What to do? Get vaccinated and boosted. When new boosters designed to attack SARS-CoV-2 or its variants appear, get those too. Even with the vaccine, you may get mild disease, but the name of the game is to prevent progress to serious disease and hospitalization. The new drugs offer reassurance. In places where the virus and infection are in decline, it is time to resume normal life.  Or at least that is my plan.

 

Richard Kessin is Emeritus Professor of Pathology and Cell Biology at the Columbia University Irving Medical Center. Reach him at Richard.Kessin@gmail.com. His website contains more information: RichardKessin.com.

 

 

       

             

 

The views expressed here are not necessarily those of The Lakeville Journal and The Journal does not support or oppose candidates for public office.

Latest News

Gilbert Kenneth Schoonmaker

WINSTED — Gilbert Kenneth Schoonmaker, of Monroe, Connecticut, passed away peacefully on July 24, 2025, at the age of 77. Born on Jan. 18, 1948, in Winsted, Connecticut to Gilbert and Alta (Bierce) Schoonmaker, Gil spent four decades enjoying life on Highland Lake before settling in Monroe.

He is lovingly survived by his wife of 56 years, Sally (Gustafson) Schoonmaker, and his two daughters, Lynn Sindland and her husband Lee of Lead Hill, Arkansas, and Deb Pikiell and her husband Tim of Bristol, Connecticut. Gil was a proud grandfather to Ozzie, Tommy, Betsy, Katie, George, Lucy, Maddie, Joey, and Julia, and he cherished his time with his eight great-grandchildren. Gilbert leaves behind his siblings Ann, Gary, Gail, Jan, and Tim.

Keep ReadingShow less
Books and bites beckon at the upcoming Sharon Summer Book Signing

Author and cartoonist Peter Steiner signed books at Sharon Summer Book Signing last summer.

Photo by Stephanie Stanton

The 27th annual Sharon Summer Book Signing at the Hotchkiss Library of Sharon will be held Friday, Aug. 1, from 4:45 to 7:30 p.m.; Saturday, Aug. 2, from 10 a.m. to 4:30 p.m.; and Sunday, Aug. 3, at noon.

Friday’s festivities will honor libraries and the power of the written word. In attendance will be 29 locally and nationally recognized authors whose books will be for sale. With a wide array of genres including historical fiction, satire, thrillers, young adult and non-fiction, there will be something for every reader.

Keep ReadingShow less
Voices from Ukraine to America come to Stissing Center July 27

Ukraine Emergency Fundraiser at The Stissing Center in 2022 raised over $120,000 for Sunflower of Peace.

Photo by Michael Churton

The spirit of Ukraine will be on display at the Stissing Center in Pine Plains on Sunday, July 27. Beginning at 5 p.m., the “Words to America from Ukraine” fundraiser is set to showcase the simultaneous beauty of Ukrainian culture and the war-time turmoil it faces, all the while fundraising in support of Ukrainian freedom.

“Words to America from Ukraine” aims to remind and spread awareness for the suffering that often gets forgotten by those who live in comfortable worlds, explained Leevi Ernits, an organizer for the event. “We are trying to make an attempt to remind people that we are human, and we are connected with human values,” she said. “With very few words, poetry can express very deep values.”

Keep ReadingShow less
Grumbling Gryphons’ set to celebrate 45th anniversary with gala and summer theater camp

Celebrating its 45th year, the Grumbling Gryphons will perform at HVRHS Friday, Aug. 1, at 7 p.m.

Photo provided

The Grumbling Gryphons Traveling Children’s Theater is preparing to celebrate its 45th year — not with fanfare, but with feathers, fabric, myth, chant, and a gala finale bursting with young performers and seasoned artists alike.

The Gryphons’ 2025 Summer Theater Arts Camp begins July 28 and culminates in a one-night-only performance gala at Housatonic Valley Regional High School on Friday, Aug. 1 at 7 p.m. Founder, playwright, and artistic director, Leslie Elias has been weaving together the worlds of myth, movement and theater for decades.

Keep ReadingShow less